Neutrophils and hair loss may seem an unlikely pairing, but emerging research highlights how these frontline immune cells can contribute to specific inflammatory scalp conditions. Neutrophils are white blood cells that ordinarily defend against infection; however, when their activity becomes dysregulated, they can drive destructive inflammation within hair follicles. This is most clearly seen in scarring alopecias such as folliculitis decalvans and dissecting cellulitis of the scalp. Understanding the neutrophil's role helps clarify why certain hair loss conditions are difficult to treat and why early specialist assessment is essential to prevent permanent follicle damage.

What Is the Role of Neutrophils in Hair Loss?

Neutrophils can damage hair follicles through enzyme release and inflammatory mediators when dysregulated, but their role is specific to certain scarring conditions — not common androgenetic alopecia or alopecia areata.

Neutrophils are a type of white blood cell that form a critical part of the body's innate immune system. They are typically the first responders to infection or tissue injury, releasing enzymes, reactive oxygen species, and inflammatory mediators to neutralise threats. Under normal circumstances, neutrophils play a protective role. However, when their activity becomes dysregulated or excessive, they can contribute to tissue damage — including within the scalp and hair follicles.

The hair follicle is considered an 'immune-privileged' site, meaning it is partially shielded from immune surveillance to prevent the body from attacking its own rapidly dividing cells. It is important to note that disruption of this immune privilege is best established in alopecia areata, which is primarily T-cell mediated rather than neutrophil-driven. Neutrophil-predominant pathology is more characteristic of specific scarring conditions such as folliculitis decalvans and dissecting cellulitis of the scalp. By contrast, other scarring alopecias — including lichen planopilaris (LPP) and discoid lupus erythematosus (DLE) — are predominantly lymphocytic in nature.

Neutrophil-derived enzymes such as elastase and matrix metalloproteinases (MMPs) can degrade the extracellular matrix surrounding hair follicles, potentially impairing their structural integrity and disrupting the normal hair growth cycle. It should be emphasised that androgenetic alopecia (male or female pattern hair loss) is not neutrophil-driven, and routine fluctuations in neutrophil count are not a recognised cause of common hair loss.

Not sure if this is normal? Chat with one of our pharmacists →

Neutrophils rarely act as the sole driver of hair loss. They often act in concert with other immune cells — such as T lymphocytes and mast cells — and their role varies considerably depending on the underlying condition. Research into the precise mechanisms linking neutrophil activity to hair follicle dysfunction is ongoing, and the clinical significance of neutrophil involvement differs across different types of alopecia.

Conditions Linking Neutrophil Activity to Hair Loss

Folliculitis decalvans and dissecting cellulitis of the scalp are the most established neutrophil-driven scarring alopecias; scalp psoriasis also involves neutrophil activity but typically causes reversible hair shedding.

Several dermatological and systemic conditions associated with neutrophil activity have been linked to hair loss, though the strength of evidence varies between them.

Folliculitis decalvans is one of the most well-established neutrophil-associated causes of scarring alopecia. In this condition, neutrophils infiltrate the hair follicle, leading to pustule formation, follicular destruction, and ultimately irreversible scarring. The exact trigger remains unclear, though Staphylococcus aureus colonisation is frequently implicated as a precipitating factor. The British Association of Dermatologists (BAD) provides patient information on this condition.

Dissecting cellulitis of the scalp (also known as perifolliculitis capitis abscedens et suffodiens) is another neutrophil-driven scarring alopecia, characterised by painful, fluctuant nodules and interconnecting sinuses. Neutrophilic infiltration plays a central role in the destructive inflammatory process. Dissecting cellulitis is part of the follicular occlusion spectrum and may coexist with hidradenitis suppurativa (HS) and acne conglobata in some patients.

Psoriasis of the scalp, while primarily a T-cell-mediated condition, also involves significant neutrophil activity. Neutrophils migrate into the epidermis to form characteristic Munro's microabscesses, and scalp psoriasis can contribute to hair shedding, though this is usually non-scarring and reversible with treatment.

Systemic conditions such as lupus erythematosus may be associated with hair loss, but the mechanisms differ by subtype. In systemic lupus erythematosus (SLE), hair loss typically presents as diffuse telogen effluvium rather than scarring alopecia. Discoid lupus erythematosus (DLE) can cause scarring alopecia, but the underlying inflammation is predominantly lymphocytic with interface dermatitis — not primarily neutrophil-driven. Certain vasculitides may also involve inflammatory changes affecting the scalp.

Some research suggests that neutrophil extracellular traps (NETs) — web-like structures released by neutrophils — may play a role in autoimmune hair loss conditions, including alopecia areata. However, this remains a speculative hypothesis with limited clinical applicability at present, and should not be interpreted as an established causal mechanism. There is no confirmed causal link between routine neutrophil count fluctuations and common androgenetic alopecia.

How Neutrophil Levels Are Assessed on the NHS

A full blood count (FBC) measures neutrophil levels as part of initial NHS investigation, but scalp biopsy and trichoscopy are key for diagnosing scarring alopecia and should not be delayed pending blood results.

If a clinician suspects an inflammatory or immune-mediated cause of hair loss, they will typically request a full blood count (FBC) as part of an initial investigation. This is a standard NHS blood test that measures the levels of different blood cells, including neutrophils. An elevated neutrophil count (neutrophilia) may indicate active infection, systemic inflammation, or, less commonly, a haematological condition. A low neutrophil count (neutropenia) can signal immunosuppression or bone marrow dysfunction.

In the context of hair loss, the FBC is rarely interpreted in isolation. Clinicians will usually request a broader panel of investigations, which may include:

• Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) — markers of systemic inflammation

• Ferritin and iron studies — iron deficiency is associated with diffuse hair shedding (telogen effluvium); confirmed deficiency should be corrected in line with NHS practice, though the relationship is associative rather than directly causal

• Thyroid function tests (TFTs) — as thyroid disorders frequently cause hair thinning

• Antinuclear antibodies (ANA) and other autoimmune markers — if lupus or another autoimmune condition is suspected

• Scalp biopsy — considered the gold standard for diagnosing scarring alopecias, providing histological evidence of the pattern and predominant cell type of inflammation

It is important to note that normal blood test results do not exclude a localised scarring alopecia; biopsy and trichoscopy findings are key when such a diagnosis is suspected, and timely dermatology referral should not be delayed pending blood results alone.

NICE Clinical Knowledge Summaries (CKS) on alopecia areata and female pattern hair loss, alongside Primary Care Dermatology Society (PCDS) guidance on primary cicatricial alopecias, provide practical frameworks for investigation in primary care. A dermatology referral via the NHS is appropriate when the diagnosis is uncertain, when scarring alopecia is suspected, or when initial treatments have not produced a satisfactory response. Trichoscopy (dermoscopy of the scalp) is increasingly used in specialist settings to assess follicular inflammation non-invasively.

Treatment Options for Inflammation-Related Hair Loss

Treatment depends on the underlying diagnosis and aims to halt scarring progression; options include oral antibiotics for folliculitis decalvans, isotretinoin for dissecting cellulitis, and NICE-guided therapies for scalp psoriasis — all under dermatologist supervision.

The management of hair loss associated with neutrophilic inflammation depends heavily on the underlying diagnosis. Treatment aims to suppress the inflammatory process, eliminate any infectious trigger, and — where possible — preserve remaining hair follicles before irreversible scarring occurs. All treatments for scarring alopecia should be initiated and supervised by a dermatologist.

For folliculitis decalvans, oral tetracyclines (such as doxycycline) are commonly used as a first-line anti-inflammatory and antimicrobial option. Where Staphylococcus aureus is confirmed on culture and sensitivity testing, combination antibiotic regimens — such as rifampicin and clindamycin — may be used. Antibiotic selection should be guided by culture and susceptibility results wherever possible, in keeping with antimicrobial stewardship principles. Rifampicin is a potent inducer of cytochrome P450 enzymes and has significant drug interactions; liver function should be monitored during treatment. Topical antiseptics, such as chlorhexidine shampoos, may be used adjunctively. In refractory cases, isotretinoin or dapsone may be considered under specialist supervision. Both are used off-label in this context in the UK. Isotretinoin is a teratogen and is subject to the MHRA Pregnancy Prevention Programme (PPP); it must only be prescribed by, or under the supervision of, a specialist with appropriate risk management measures in place. Dapsone requires G6PD testing before initiation, and ongoing full blood count and liver function monitoring during treatment.

Worried about interactions with other medications? Speak to one of our pharmacists →

For dissecting cellulitis, isotretinoin is often the preferred systemic agent, as it reduces sebaceous gland activity and dampens the inflammatory response; its use in this indication is off-label in the UK and subject to the same PPP requirements as above. Biologics such as adalimumab (a TNF-alpha inhibitor) have shown promise in treatment-resistant cases; their use in dissecting cellulitis is off-label in the UK, and patients should be screened for tuberculosis, hepatitis B and C, and other infections before initiation, with ongoing monitoring as per specialist guidance.

For scalp psoriasis, treatment follows NICE guidance (Psoriasis: assessment and management) and includes:

• Topical corticosteroids and vitamin D analogues, including combined calcipotriol/betamethasone scalp formulations, as first-line options

• Coal tar-based shampoos

• Systemic agents such as methotrexate for moderate-to-severe disease; methotrexate requires pre-treatment screening (FBC, renal and liver function, hepatitis serology) and regular monitoring during treatment, in line with NICE and BNF guidance

• Biologics (e.g., secukinumab) for moderate-to-severe disease in line with relevant NICE Technology Appraisals; pre-treatment infection screening and ongoing monitoring are required

General anti-inflammatory approaches, including topical or intralesional corticosteroids, may be used across several inflammatory alopecias to reduce localised immune activity.

Patients should be counselled that treatment goals in scarring alopecia are primarily to halt progression rather than to restore lost hair. Patients who experience suspected side effects from any medication should report these to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

When to Seek Medical Advice About Hair Loss

Patients should see their GP promptly if they notice rapid or patchy hair loss, scalp pustules, tenderness, boggy nodules, or systemic symptoms, as early referral is essential when scarring alopecia is suspected.

Hair loss is a common concern, and whilst it is not always a sign of serious illness, certain features warrant prompt medical attention. Patients should contact their GP if they notice any of the following:

• Rapid or patchy hair loss developing over a short period

• Scalp symptoms such as persistent redness, scaling, pustules, pain, or tenderness

• Features suggestive of scarring disease, including boggy or tender nodules, tufted follicles (multiple hairs emerging from a single follicular opening), yellow crusting, or draining sinuses — these warrant prompt assessment

• Scarring or skin changes on the scalp, which may indicate a destructive inflammatory process

• Systemic symptoms accompanying hair loss, including fatigue, joint pain, rash, or unexplained weight loss — which could suggest an underlying autoimmune or systemic condition

• Hair loss in children, which always warrants evaluation

• Significant psychological distress related to hair loss, as this can have a considerable impact on quality of life and may benefit from both medical and psychological support; NHS psychological therapies (IAPT/Talking Therapies) services may be accessible via GP referral

It is worth noting that the most common causes of hair loss — such as androgenetic alopecia, telogen effluvium (often triggered by stress, illness, or nutritional deficiency), and alopecia areata — are not primarily neutrophil-driven. However, a thorough clinical assessment is necessary to distinguish these from rarer inflammatory conditions.

GPs will typically conduct an initial assessment, arrange relevant blood tests, and refer to a dermatologist where appropriate. NHS dermatology services can offer specialist investigation including scalp biopsy and trichoscopy. Early referral is particularly important when scarring alopecia is suspected, as timely intervention offers the best chance of limiting permanent follicle damage — and should not be delayed even if initial blood tests are normal.

Patients are encouraged to keep a record of when hair loss began, any associated symptoms, recent illnesses or stressors, and any medications they are taking — as this information greatly assists clinical assessment. The NHS website provides patient-facing information on hair loss and guidance on when to seek help.

Frequently Asked Questions